- Home
- REX vs ATAI Comparison
REX vs ATAI Comparison
Compare REX & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | REX | ATAI |
|---|---|---|
| Founded | 1980 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.6B |
| IPO Year | 1994 | 2025 |
Fundamental Metrics
Financial Performance| Metric | REX | ATAI |
|---|---|---|
| Price | $44.12 | $5.18 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $15.88 |
| AVG Volume (30 Days) | 187.0K | ★ 5.6M |
| Earning Date | 05-27-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.56 | N/A |
| Revenue | ★ $650,487,000.00 | $4,089,000.00 |
| Revenue This Year | $19.45 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $77.52 | ★ N/A |
| Revenue Growth | 1.24 | ★ 1227.60 |
| 52 Week Low | $30.02 | $2.16 |
| 52 Week High | $64.95 | $6.73 |
Technical Indicators
Market Signals| Indicator | REX | ATAI |
|---|---|---|
| Relative Strength Index (RSI) | 42.17 | 70.85 |
| Support Level | $41.84 | $4.96 |
| Resistance Level | $49.21 | $5.51 |
| Average True Range (ATR) | 1.41 | 0.33 |
| MACD | -0.02 | 0.09 |
| Stochastic Oscillator | 35.36 | 88.36 |
Price Performance
Historical ComparisonAbout REX REX American Resources Corporation
REX American Resources Corp operates as a holding company that engages in investments in alternative energy and ethanol production entities. Its operating segments include Ethanol and By-Products. Its products include Ethanol, dried distillers grains, modified distillers grains, Distillers corn oil, Modified distillers grains, and Other.
About ATAI ATAI Life Sciences N.V.
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.